DE69933653D1 - Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen - Google Patents

Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen

Info

Publication number
DE69933653D1
DE69933653D1 DE69933653T DE69933653T DE69933653D1 DE 69933653 D1 DE69933653 D1 DE 69933653D1 DE 69933653 T DE69933653 T DE 69933653T DE 69933653 T DE69933653 T DE 69933653T DE 69933653 D1 DE69933653 D1 DE 69933653D1
Authority
DE
Germany
Prior art keywords
ribozyms
restricting
expression
ccr5 receptor
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933653T
Other languages
English (en)
Other versions
DE69933653T2 (de
Inventor
J Rossi
Laurence Cagnon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Application granted granted Critical
Publication of DE69933653D1 publication Critical patent/DE69933653D1/de
Publication of DE69933653T2 publication Critical patent/DE69933653T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69933653T 1998-03-11 1999-03-05 Zur Hemmung der Expression des CCR5-Rezeptors befähigte Ribozyme Expired - Lifetime DE69933653T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38741 1987-04-15
US09/038,741 US6100087A (en) 1998-03-11 1998-03-11 Ribozymes targeted to human CCR5 mRNA
PCT/US1999/005011 WO1999046372A2 (en) 1998-03-11 1999-03-05 Ribozymes capable of inhibiting the expression of the ccr5 receptor

Publications (2)

Publication Number Publication Date
DE69933653D1 true DE69933653D1 (de) 2006-11-30
DE69933653T2 DE69933653T2 (de) 2007-08-23

Family

ID=21901629

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933653T Expired - Lifetime DE69933653T2 (de) 1998-03-11 1999-03-05 Zur Hemmung der Expression des CCR5-Rezeptors befähigte Ribozyme

Country Status (8)

Country Link
US (1) US6100087A (de)
EP (1) EP1062330B1 (de)
JP (1) JP4330797B2 (de)
AT (1) ATE342969T1 (de)
AU (1) AU2989799A (de)
CA (1) CA2323109A1 (de)
DE (1) DE69933653T2 (de)
WO (1) WO1999046372A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
WO1996041020A1 (en) * 1995-06-07 1996-12-19 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) * 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU5086400A (en) * 1999-05-21 2000-12-12 Oxford Biomedica (Uk) Limited Improved retroviral production
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
DE60233333D1 (de) 2001-09-13 2009-09-24 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2003281858A1 (en) * 2002-07-26 2004-02-23 Consejo Superior De Investigaciones Cientificas Multifunctional genetic constructions having a high capacity to inhibit the expression of ccr5 on the cell surface
CA2494116A1 (en) * 2002-07-31 2004-03-25 City Of Hope Adenoviral va1 pol iii expression system for rna expression
CA2495556A1 (en) * 2002-08-01 2004-02-12 City Of Hope Methods and kits for synthesis of sirna expression cassettes
AU2003296945A1 (en) * 2002-12-12 2004-07-09 Chiron Corporation Device and method for in-line blood testing using biochips
US7943130B2 (en) 2003-12-11 2011-05-17 Yale University Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
AU2006272750B2 (en) * 2005-07-22 2011-09-29 Cytodyn, Inc. Methods for reducing viral load in HIV-1-infected patients
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
US8309791B2 (en) 2008-07-16 2012-11-13 Recombinectics, Inc. Method for producing a transgenic pig using a hyper-methylated transposon

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
DE69739366D1 (de) * 1996-03-01 2009-05-28 Euroscreen Sa Aktive und inactive CC-Chemokinrezeptoren und Nukleinsäuremoleküle, die für diesen Rezeptor kodieren
AU3375697A (en) * 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
WO1998005798A1 (en) * 1996-08-08 1998-02-12 The Aaron Diamond Aids Research Center Hiv coreceptor mutants
US5939538A (en) * 1996-10-25 1999-08-17 Immusol Incorporated Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA
JP4312957B2 (ja) * 1998-01-15 2009-08-12 キングス・カレツジ・ロンドン Ｃｃｒ５あるいはｃｘｃｒ４を開裂するリボザイム核酸

Also Published As

Publication number Publication date
US6100087A (en) 2000-08-08
WO1999046372A3 (en) 1999-11-04
JP2002505876A (ja) 2002-02-26
CA2323109A1 (en) 1999-09-16
EP1062330B1 (de) 2006-10-18
ATE342969T1 (de) 2006-11-15
JP4330797B2 (ja) 2009-09-16
EP1062330A2 (de) 2000-12-27
DE69933653T2 (de) 2007-08-23
WO1999046372A2 (en) 1999-09-16
AU2989799A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
DE69933653D1 (de) Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen
DE69942485D1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
DE69637816D1 (de) Der expression von genen, welche spezifisch sind für die stärkebiosynthese
PT1355889E (pt) Derivados diamina triazole substituidos como inibidores de cinase
MXPA03000809A (es) Polimero de polisiloxano, procedimiento para su preparacion y su uso.
ATE550025T1 (de) Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna)
DE69403642T2 (de) 7-deazapurin modifizierte oligonukleotide
HK1029595A1 (en) Cyclic antagonists of c5a receptors and g protein-coupled receptors
ATE481926T1 (de) Verfahren zum trainieren kognitive fähigkeiten
WO2002033116A3 (en) Nucleic acid ligands to the prostate specific membrane antigen
DE60126337D1 (de) Verfahren zum screenen für gpr40-liganden
DE69635998D1 (de) Nachweisverfahren für verbindungen, welche die somatostatin- und insulinproduktion stimulieren
ES2160410T3 (es) Preparados de complejos de protrombina inmunotolerantes.
ATE486059T1 (de) Synthese und verfahren zu deren verwendung von tetrahydroindolon analogen und derivaten
DK0906443T3 (da) Generering af replikerende molekyler in vivo
DE60031723D1 (de) Verfahren und system zum anbieten und erzeugen von accounts für potentielle benutzer eines instant-messaging-systems
DK1385993T3 (da) Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE450003T1 (de) Komputergesteuerte verfahren und system zum implementieren von verteilten anwendungen
TR200501974T2 (tr) Geotekstillerin tespitinde tekstil yardımcı maddesinin uygulanması yöntemi ve tertibatı.
ATE333508T1 (de) Verfahren in vitro zum einbringen von nukleinsäure in eine zelle (transfektion) mittels calciumphosphat
SE0003126D0 (sv) Method of treatment
MY141850A (en) Pharmaceutically active diazepanes
ATE315335T1 (de) Indolocarbazol-antikrebsmittel und verfahren zu ihrer verwendung
HUP0204460A2 (en) Method for increasing the gene expression of transfected genes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition